East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Adalimumab
Adalimumab
Routinely available
NICE (TA329 (SMC 800/12))
04/12/2024

Indication

Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Therapeutic Area

Gastro-intestinal system

Status Description

Routinely available in line with national guidance

Formulation

-

Comments

Refer to pathway or local board guidelines for preferred formulation

Link to Advice

TA329 (SMC 800/12)

Advice Published

25/02/2015